Skip to content

Puberty in Girls Followed for Cystic Fibrosis

Epidemiological Study of the Progress of Puberty in Girls Followed for Cystic Fibrosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02562911
Acronym
EPIMUCO
Enrollment
166
Registered
2015-09-29
Start date
2013-01-31
Completion date
2015-12-31
Last updated
2017-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

cystic fibrosis, menstrual cycle, puberty

Brief summary

In the general population, age of puberty, and age of menarche in girls, are closely correlated with those of their mother. The severity of chronic disease has an impact on the stature, the weight gain and the onset of puberty: age of menarche is even later that chronic illness is serious. Cystic fibrosis is one of the major chronic diseases of children. Neonatal screening is organized since 2002, most girls with cystic fibrosis therefore currently have a very specialized and early care. Older patients were diagnosed during childhood. The optimization of the nutritional and respiratory management has allowed over the past two decades a significant improvement in the survival of these patients. Most young people reach adulthood, puberty and reproductive desire are a crucial issue in the care of these young adults. In literature, it is often noted an age of menarche delayed an average of 2 years compared to the general population, but correlated with the age of menstruation from the mothers. The factors involved in the conduct of cycles in the girl followed for cystic fibrosis are poorly known and there are few data on the characteristics of cycles. The menstrual irregularity and amenorrhoea episodes concern nearly half of women. On the pathophysiological level, studies in animals show that there is a direct effect of CFTR (Cystic Fibrosis Transmembrane Regulator) on the hypothalamic pituitary gonadal and reproductive capacity in mice. The literature data on the pubertal development, fertility and hormonal profile of these girls are for studies with low numbers and are very old. There is to date no French cohort study on this topic. The study is a multicenter cross-sectional descriptive study for pubertal and gynecological characteristics in girls followed annually in the reference centers Cystic Fibrosis two inter-region.

Interventions

PROCEDUREData collection

* Clinical examination * Complete pelvic ultrasound abdominal ultrasound * Bone age: X-ray * biological examination * Lung function assessed by the Maximum Volume Expired * Brasfield radiological score (if available)

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient diagnosed with cystic fibrosis * Girl aged 8 years of age, adolescents and young adults, had period or not, * visit the Reference and Competence Center of Cystic Fibrosis. * Affiliated to a social security scheme

Exclusion criteria

* Lack of consent of the legal representative or the relevant patient. * Patient majoring in legal disability or minor patient whose legal representative is legal disability

Design outcomes

Primary

MeasureTime frame
The age of menarche in girls followed for cystic fibrosis in FranceDay 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026